<i>SRD5A1</i>and<i>SRD5A2</i>are Associated with Treatment for Benign Prostatic Hyperplasia with the Combination of 5α-Reductase Inhibitors and α-Adrenergic Receptor Antagonists

Abstract

SRD5A1 and SRD5A2 single nucleotide polymorphisms are significantly associated with the clinical characteristics of benign prostatic hyperplasia and the efficacy of benign prostatic hyperplasia treatment.